永井 礼子 (ナガイ アヤコ)

北海道大学病院 小児・周産・女性科 小児科特任助教

研究者基本情報

■ 学位
  • 医学博士
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 10622160
J-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 循環器内科学
  • ライフサイエンス, ゲノム生物学
  • ライフサイエンス, 胎児医学、小児成育学

経歴

■ 経歴
委員歴
  • 2026年 - 現在
    日本循環器学会, 用語部会委員
  • 2025年 - 現在
    Japanese Association of CHD-PH Registry 運営委員
  • 2025年 - 現在
    日本小児循環器学会, 和文誌編集委員
  • 2025年 - 現在
    日本小児循環器学会, 研究委員
  • 2025年 - 現在
    米国心臓協会 Fellow of the American Heart Association (FAHA)
  • 2024年 - 現在
    日本小児循環器学会, 小児心不全薬物治療ガイドライン作成班 班員
  • 2024年 - 現在
    日本肺高血圧・肺循環学会, 小児肺循環研究部会委員
  • 2024年 - 現在
    日本肺高血圧・肺循環学会, 小児循環器連携委員会委員
  • 2023年 - 現在
    日本小児循環器学会, ジョイントセッション委員
  • 2022年 - 現在
    日本肺高血圧・肺循環学会, 評議員
  • 2020年 - 現在
    日本小児循環器学会, 評議員
  • 2023年 - 2025年
    日本肺高血圧・肺循環学会, 先天性心疾患を伴う肺高血圧症(CHD-PH)診療ガイドライン2025 作成委員
  • 2023年 - 2025年
    日本小児循環器学会, 幹事
  • 2022年 - 2025年
    日本小児循環器学会, associate editor
  • 2022年 - 2024年
    日本循環器学会, ダイバーシティ推進委員
  • 2021年 - 2023年
    日本小児循環器学会, 研究委員

研究活動情報

■ 受賞
  • 2025年03月, 公益財団法人宮田心臓病研究振興基金 未成年心臓血管病の学究等に対する奨励金
  • 2024年07月, 日本小児循環器学会 Case Report Award
  • 2024年03月, 日本循環器学会 女性研究者奨励賞
  • 2021年07月, 北海道心臓協会研究開発調査助成
  • 2021年07月, Miyata Foundation Award 日本小児循環器学会研究奨励賞
  • 2020年12月, 公益財団法人宮田心臓病研究振興基金 未成年心臓血管病の学究等に対する奨励金
  • 2019年04月, 北海道小児循環器研究会賞
  • 2017年11月, Travel Award for Women Cardiologists (JCS/TAWC)
  • 2013年03月, 日本循環器学会小児循環器賞
  • 2012年11月, American Heart Association Scientific Sessions Poster Winner
■ 論文
  • Registry-based estimation of cardiac event-free survival in congenital heart disease complicated by pulmonary hypertension: A nationwide registry study from Japan.
    Taku Ishii; Tatsuhiko Anzai; Keiko Uchida; Susumu Hosokawa; Naofumi F Sumitomo; Hidekazu Ishida; Keiichi Hirono; Jun Muneuchi; Ayako Chida-Nagai; Ryo Inuzuka; Hirofumi Sawada; Sayo Suzuki; Jun Maeda; Hisaaki Aoki; Lisheng Lin; Takashi Murakami; Yusuke Nakano; Tatsuya Onishi; Takuya Wakamiya; Kei Inai; Shinichi Takatsuki; Atsushi Yao; Shigetoyo Kogaki; Hiroyuki Fukushima; Yuichi Tamura; Kunihiko Takahashi; Hiroyuki Yamagishi; Shozaburo Doi
    International journal of cardiology. Congenital heart disease, 25, 100679, 100679, 2026年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pulmonary hypertension (PH) is a major determinant of outcomes in congenital heart disease (CHD), yet tools for individualized prognostic estimation are limited. This study aimed to develop an exploratory, clinically oriented prediction model for estimating cardiac event-free survival in patients with CHD-PH. METHODS: Data from the nationwide Japanese Association of CHD-PH Registry were analyzed in a retrospective cohort derived from a prospectively maintained registry. Cardiac event-free survival was evaluated using Cox proportional hazards models incorporating prespecified, routinely available clinical and hemodynamic variables. Cardiac events were defined as death, transplantation, clinical worsening requiring treatment escalation, or PH-related hospitalization. RESULTS: A total of 224 patients were included, and 23 experienced 29 cardiac events during a median follow-up of 1.5 years. These included 7 cardiovascular deaths, 1 lung transplantation, and 1 atrial septostomy, 13 cases of clinical worsening. The cardiac event-free survival rates were 94.0% and 86.2% at 1 and 2 years, respectively. In multivariable analysis, trisomy 21 (hazard ratio [HR] 3.63), elevated pulmonary vascular resistance index (PVRI; HR 13.2), and elevated central venous pressure (CVP; HR 3.27) were associated with worse outcomes. These associations were consistent in sensitivity and subgroup analyses. Model-based estimates demonstrated risk gradients across clinically relevant profiles and were incorporated into a prototype prediction tool. CONCLUSIONS: An exploratory pragmatic prediction model for cardiac event-free survival in CHD-PH was developed using nationwide registry data. These findings support the feasibility of a registry-based prognostic framework; however, further validation is required before clinical application.
  • Repeated epicardial lead dislodgement in a child with trisomy 21 and complete atrioventricular block: A case report.
    Tatsunori Itabashi; Ayako Chida-Nagai; Yuto Suzuki; Daisuke Sasaki; Jiro Abe; Nobuyasu Kato; Taro Temma; Hirokuni Yamazawa; Atsuhito Takeda
    Journal of cardiology cases, 34, 2, 46, 48, 2026年08月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), UNLABELLED: Lead dislodgement is a rare complication of epicardial leads, which are generally chosen for pacemaker implantation in pediatric patients. Here, we report the case of a 12-year-old girl with trisomy 21 and a complete atrioventricular septal defect. The patient required epicardial pacemaker implantation; however, the epicardial left ventricular lead unexpectedly dislodged twice. This report discusses the potential causes and outlines our management strategy. LEARNING OBJECTIVE: Age, body size, growth-related changes, lifestyle, and durability complicate pacemaker implantation in children. Therefore, epicardial leads are commonly used for pacemaker implantation. Epicardial leads are not limited by body size or disease, and venous obstruction is not an issue; however, they are more invasive. Pacemaker implantation in pediatric patients with congenital heart disease requires meticulous consideration of patient-specific anatomical and physiological factors. Careful preoperative discussions among pediatric and adult cardiology teams, as well as cardiovascular surgery teams, are essential to optimize patient outcomes.
  • Development of a Protective Device to Prevent Damage to an Endotracheal Tube Caused by the Eruption of Deciduous Teeth.
    Jimei Zhao; Kaoru Shigeta; Risa Yamamoto; Sara Watanabe; Ayako Chida-Nagai; Hirokuni Yamazawa; Tatsuya Akitomo; Koichi Nakamura
    Reports (MDPI), 9, 3, 2026年07月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), In patients undergoing endotracheal intubation and mechanical ventilation, damage to the endotracheal tube or inflation line is a potential risk with life-threatening consequences. Although various devices and bite blocks have been developed to secure the endotracheal tube and prevent its dislodgement or damage, they are not suitable for children or newborns. We describe a 1-year-and-2-month-old girl who required long-term endotracheal intubation and mechanical ventilation. The eruption of the lower deciduous incisors caused damage to the inflation line. A mouthguard was not appropriate because her teeth had erupted only slightly, and the retention was insufficient. After collaborating with a dental technician to fabricate a protective device, we were able to provide the optimal treatment while minimizing invasiveness to the patient. It is necessary to collaborate with other professionals as a team to select the optimal medical care tailored to each patient.
  • Biallelic loss-of-function variants in PTGIS cause recurrent cervical internal carotid artery vasospasm.
    Hiroyuki Akagawa; Hideaki Onda; Yosuke Moteki; Takatoshi Sorimachi; Ryoichi Saito; Atsuko Nihira; Takahiro Hori; Akikazu Nakamura; Makiko Terada; Takamura Nagasaka; Ayako Chida-Nagai; Tomohiro Aoki; Yuichi Kubota
    International journal of stroke : official journal of the International Stroke Society, 17474930261449005, 17474930261449005, 2026年04月25日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Recurrent cervical internal carotid artery vasospasm (RCICAV) is a rare cause of ischemic stroke in young adults. However, its pathophysiology remains largely unknown. RCICAV is a life-threatening condition, sometimes accompanied by coronary spasmodic angina in addition to severe stroke, highlighting the need for further investigation of its etiology and therapeutic approaches. AIMS: This study aimed to identify the genetic basis of Japanese families harboring RCICAV. METHODS: Whole-exome and Sanger sequencing analyses were performed in five Japanese patients from four families (two affected siblings and three unrelated sporadic patients) and seven unaffected members from three families enrolled from October 2016 to May 2025. RCICAV was diagnosed using magnetic resonance angiography, which demonstrated vasospasm of the cervical portion of the internal carotid artery during the event and normalization during remission. In vitro and ex vivo analyses of the detected variants were performed to verify functional deficiencies. RESULTS: RCICAV was found to be an autosomal recessive disorder caused by biallelic loss-of-function variants in the PTGIS gene, which encodes the prostacyclin synthase. Three splice-site and nonsense variants, c. 1358+2 T>C, p.W39X, and p. E314X, were identified in five patients from four families in either homozygous or compound heterozygous states. The c.1358+2T>C variant caused exon 9 skipping (p.V403Ifs*24), which was confirmed by a minigene assay and reverse transcription polymerase chain reaction using RNA extracted from peripheral blood leukocytes of a homozygous patient. Human carotid artery endothelial cells expressing these truncated variants exhibited markedly reduced PTGIS protein and prostacyclin metabolite production. CONCLUSIONS: The results indicate that prostacyclin synthase deficiency is the core pathology of RCICAV. Given that prostacyclin is a potent vasodilator, impaired biosynthesis is consistent with the disease mechanism and may serve as a promising therapeutic target to prevent life-threatening events, including severe stroke and angina.
  • Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries.
    Keiichi Hirono; Keiko Uchida; Taku Ishii; Hidekazu Ishida; Shinichi Takatsuki; Hiroyuki Fukushima; Kei Inai; Susumu Hosokawa; Reina Ishizaki; Hirofumi Sawada; Naofumi F Sumitomo; Ayako Chida-Nagai; Yuichi Ishikawa; Hirohiko Motoki; Atsushi Yao; Shigetoyo Kogaki; Hiroyuki Yamagishi; Shozaburo Doi
    Journal of clinical medicine, 15, 3, 2026年01月30日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background: Pulmonary atresia (PA) with ventricular septal defect (VSD) and major aortopulmonary collateral arteries (MAPCAs), a life-threatening congenital heart defect (CHD), is frequently associated with abnormal pulmonary blood flow and vascular remodeling, causing hypoxia and heart failure. Segmental pulmonary hypertension (PH), a distinct PH type, may exist in some patients. Pulmonary vasodilators have been considered for treatment; however, evidence of their efficacy and safety remains lacking. Methods: A systematic review was conducted using PubMed, MEDLINE, The Cochrane Library, and Ichushi Web, encompassing studies from inception to May 2023. Inclusion criteria focused on patients with PA/VSD/MAPCAs treated with PH medications. Results: Of 86 studies screened, 6 met the inclusion criteria, including 1 cohort study and 5 case reports, comprising 22 patients. The most frequently administered medications were sildenafil (14 cases) and bosentan (12 cases), with 16 patients receiving monotherapy. Clinical improvements were observed in pulmonary vascular resistance (8/8 patients), oxygen saturation (8/19 patients), and symptoms (19/21 patients). Adverse effects were noted in five patients, including treatment discontinuation in two. Conclusions: PH medications may benefit some patients with PA/VSD/MAPCAs; however, the extremely limited sample size (n = 22) and substantial heterogeneity in anatomy, age, surgical status, and treatment regimens severely limit interpretability and clinical applicability. Considering the potential benefits and risks associated with these medications, their use should be considered cautiously and restricted to specialized centers with expertise in CHD and PH management.
  • Diagnosis of a Neonate With Long QT Syndrome and Severe Complications Delayed due to an Unrecognized Familial History.
    Kaho Kawabata; Ayako Chida-Nagai; Kenta Takeda; Ryota Honjo; Daisuke Sasaki; Hirokuni Yamazawa; Yosuke Kaneshi
    Case reports in pediatrics, 2025, 5621484, 5621484, 2025年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Long QT syndrome (LQTS) is a hereditary arrhythmic disorder associated with sudden cardiac death. We report a neonatal case of congenital LQTS that went undiagnosed in utero, leading to severe postnatal complications. A male preterm infant was delivered by emergency cesarean section due to fetal hydrops. Shortly after birth, he developed respiratory failure and metabolic acidosis, followed by ventricular tachycardia and torsades de pointes requiring prolonged resuscitation. During cardiopulmonary resuscitation, the father collapsed, and it was subsequently established that he had been receiving treatment for LQTS. The paternal grandmother also had the same diagnosis. Genetic testing performed for the infant identified a pathogenic KCNH2 variant (c.1714G > A, p.Gly572Ser), confirming Type 2 LQTS. Despite antiarrhythmic therapy and ventricular pacing, the patient developed severe intraventricular hemorrhage and hydrocephalus. This case serves to emphasize the importance of obtaining a detailed family history and the need for effective communication among obstetricians, neonatologists, and cardiologists. In this instance, a lack of awareness regarding familial LQTS contributed to a delay in diagnosis and intervention. Our findings highlight the essential roles played by early detection and prenatal risk assessment through family screening and genetic testing for preventing life-threatening arrhythmia and improving outcomes in congenital LQTS.
  • Secondary Cardiomyopathy Due to Selenium Deficiency: Multidimensional Cardiac Evaluation and Treatment.
    Yuya Fujita; Ayako Chida-Nagai; Naoyuki Shibukawa; Itabashi Tatsunori; Yuto Suzuki; Daisuke Sasaki; Hirokuni Yamazawa; Atsuhito Takeda
    JACC. Case reports, 30, 24, 104665, 104665, 2025年08月20日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Selenium deficiency can cause cardiomyopathy; however, the underlying mechanisms remain unclear. We report a case of cardiomyopathy associated with selenium deficiency in a patient with long-term enteral nutrition. CASE SUMMARY: A 2-year-old boy with gastrointestinal allergy developed secondary cardiomyopathy due to selenium deficiency resulting from an elemental diet. He presented with reduced left ventricular function and dilated ventricles. Serum selenium levels were undetectable. Myocardial scintigraphy showed perfusion-metabolism mismatches and fibrosis. Selenium supplementation and medications for heart failure led to significant cardiac recovery over a period of 1 year. DISCUSSION: The patient's congenital heart disease allowed for evaluation before the onset of selenium deficiency cardiomyopathy. Myocardial scintigraphy revealed a characteristic perfusion-metabolism imbalance. Both selenium supplementation and treatment for ischemic heart disease were effective in improving cardiac function. TAKE-HOME MESSAGES: Myocardial scintigraphy is useful in diagnosing selenium deficiency cardiomyopathy. Selenium supplementation and management of ischemic heart disease are essential for treatment.
  • Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors.
    Ayako Chida-Nagai; Yukayo Terashita; Shinsuke Hirabayashi; Hirokuni Yamazawa; Yuko Cho; Atsushi Manabe
    Pulmonary circulation, 15, 3, e70165, 2025年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Pulmonary hypertension (PH) is a severe complication observed in pediatric patients after hematopoietic cell transplantation or chemotherapy. A review of records at Hokkaido University Hospital (2014-2024) identified four cases of PH, each with different etiologies, including pulmonary arterial hypertension, pulmonary veno-occlusive disease, and microthromboembolism. Contributing factors included splenic atrophy, corticosteroid-responsive inflammation, and potential drug-induced vascular remodeling. Although transient PH usually resolves, late-onset PH emphasizes the need for long-term echocardiographic monitoring. These findings underscore the importance of individualized management, avoiding pulmonary vasodilators without proper evaluation, and addressing underlying conditions such as thrombotic microangiopathy or interstitial lung disease.
  • Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats
    Ayako Chida-Nagai; Naoki Masaki; Hiroki Sato; Tatsuya Kato; Emi Takakuwa; Yoshihiro Matsuno; Atsushi Manabe; Atsuhito Takeda
    Frontiers in Pharmacology, 16, 1577570, Frontiers Media SA, 2025年04月30日, [査読有り], [国際誌]
    研究論文(学術雑誌), Introduction

    Pulmonary arterial hypertension (PAH) remains a challenge to tackle despite various available medications. Metformin, although promising, has major adverse effects; the use of an appropriate drug delivery method may improve its efficacy and safety. The aim of this study was to develop a novel treatment for PAH using metformin. We developed a novel approach of using low-dose metformin encapsulated in pulmonary artery-targeted nanocapsules to alleviate PAH while avoiding adverse effects.

    Methods

    Metformin-loaded lung-targeted nanocapsules (MET nanocapsules) were created using a specific lipid composition, including cationic lipids. Their uptake and effects on cell viability were assessed in human pulmonary arterial smooth muscle cells (hPASMCs) from healthy individuals and patients with PAH. Their therapeutic effects were assessed in a PAH rat model. The safety of MET nanocapsules was confirmed using rat serum biochemical tests.

    Results

    We successfully prepared MET nanocapsules and demonstrated their effectiveness in inhibiting PASMC proliferation. In PAH model rats, MET nanocapsule treatment led to improved hemodynamics, right ventricular hypertrophy, and pulmonary arterial medial thickening. The nanocapsules effectively accumulated in the lungs of PAH model rats.

    Conclusion

    Intravenous administration of MET nanocapsules is a safe and innovative therapeutic approach for PAH. This method could improve PAH treatment outcomes while minimizing adverse effects, with potential applications in other types of pulmonary hypertension.
  • 筋ジストロフィー患者の末梢血単核球におけるミトコンドリア呼吸能力の変化(Alteration of mitochondrial respiratory capacity in peripheral mononuclear blood cells from muscular dystrophy patients)
    山澤 弘州; 武田 充人; 永井 礼子; 佐々木 大輔; 佐藤 逸美; 板橋 立紀; 鈴木 祐人; 横田 卓
    日本小児科学会雑誌, 129, 2, 189, 189, (公社)日本小児科学会, 2025年02月
    英語
  • Whole-exome sequencing reveals the genetic causes and modifiers of moyamoya syndrome.
    Akikazu Nakamura; Shunsuke Nomura; Shoko Hara; Thiparpa Thamamongood; Taketoshi Maehara; Tadashi Nariai; Shasha Khairullah; Kay Sin Tan; Kenko Azuma; Ayako Chida-Nagai; Yoshiyuki Furutani; Takahiro Hori; Koji Yamaguchi; Takakazu Kawamata; Constantin Roder; Hiroyuki Akagawa
    Scientific reports, 14, 1, 22720, 22720, 2024年10月04日, [査読有り], [国際共著], [国際誌]
    英語, 研究論文(学術雑誌), Moyamoya vasculopathy secondary to various genetic disorders is classified as moyamoya syndrome (MMS). Recent studies indicate MMS occurs due to a combination of genetic modifiers and causative mutations for the primary genetic disorders. We performed whole-exome sequencing (WES) in 13 patients with various genetic disorders who developed MMS. WES successfully revealed the genetic diagnoses of neurofibromatosis type 1 (NF-1), Down syndrome, multisystemic smooth muscle dysfunction syndrome, Noonan syndrome, and alpha thalassemia. The previously reported modifier genes, RNF213 and MRVI1, were confirmed in the NF-1 and Down syndrome cases. Further analysis revealed rare hypomorphic variants in the causative genes of the primary disorders underlying MMS, such as Alagille syndrome and Rasopathies, conferred susceptibility to MMS. Genes involved in the development of pulmonary arterial hypertension (PAH), such as ABCC8 and BMPR2, were also identified as potential modifiers. The rare variants in the MMS and PAH genes were significantly enriched in the eight Japanese patients with MMS compared with the 104 Japanese individuals from the 1000 Genomes Project. Disease genes associated with the arterial occlusive conditions represented by those of Rasopathies and PAH may provide novel diagnostic markers and future therapeutic targets for MMS as well as moyamoya disease with an unknown cause.
  • Impact of the COVID-19 pandemic on pediatric out-of-hospital cardiac arrest outcomes in Japan.
    Ayako Chida-Nagai; Hiroki Sato; Hirokuni Yamazawa; Atsuhito Takeda; Naohiro Yonemoto; Yoshio Tahara; Takanori Lkeda
    Scientific reports, 14, 1, 11246, 11246, 2024年05月16日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), This study investigates the impact of the COVID-19 pandemic on pediatric out-of-hospital cardiac arrest (OHCA) outcomes in Japan, aiming to address a critical research gap. Analyzing data from the All-Japan Utstein registry covering pediatric OHCA cases from 2018 to 2021, the study observed no significant changes in one-month survival, neurological outcomes, or overall performance when comparing the pre-pandemic (2018-2019) and pandemic (2020-2021) periods among 6765 cases. However, a notable reduction in pre-hospital return of spontaneous circulation (ROSC) during the pandemic (15.1-13.1%, p = .020) was identified. Bystander-initiated chest compressions and rescue breaths declined (71.1-65.8%, 22.3-13.0%, respectively; both p < .001), while bystander-initiated automated external defibrillator (AED) use increased (3.7-4.9%, p = .029). Multivariate logistic regression analyses identified factors associated with reduced pre-hospital ROSC during the pandemic. Post-pandemic, there was no noticeable change in the one-month survival rate. The lack of significant change in survival may be attributed to the negative effects of reduced chest compressions and ventilation being offset by the positive impact of widespread AED availability in Japan. These findings underscore the importance of innovative tools and systems for safe bystander cardiopulmonary resuscitation during a pandemic, providing insights to optimize pediatric OHCA care.
  • Identification of Prostaglandin I2 Synthase Rare Variants in Patients With Williams Syndrome and Severe Peripheral Pulmonary Stenosis.
    Ayako Chida-Nagai; Hiroyuki Akagawa; Saori Sawai; Yue-Jiao Ma; Satoshi Yakuwa; Jun Muneuchi; Kazushi Yasuda; Hirokuni Yamazawa; Toshiyuki Yamamoto; Emi Takakuwa; Utano Tomaru; Yoshiyuki Furutani; Tatsuya Kato; Gen Harada; Kei Inai; Toshio Nakanishi; Atsushi Manabe; Atsuhito Takeda; Zhi-Cheng Jing
    Journal of the American Heart Association, e032872, 2024年04月19日, [査読有り], [国際共著], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Peripheral pulmonary stenosis (PPS) is a condition characterized by the narrowing of the pulmonary arteries, which impairs blood flow to the lung. The mechanisms underlying PPS pathogenesis remain unclear. Thus, the aim of this study was to investigate the genetic background of patients with severe PPS to elucidate the pathogenesis of this condition. METHODS AND RESULTS: We performed genetic testing and functional analyses on a pediatric patient with PPS and Williams syndrome (WS), followed by genetic testing on 12 patients with WS and mild-to-severe PPS, 50 patients with WS but not PPS, and 21 patients with severe PPS but not WS. Whole-exome sequencing identified a rare PTGIS nonsense variant (p.E314X) in a patient with WS and severe PPS. Prostaglandin I2 synthase (PTGIS) expression was significantly downregulated and cell proliferation and migration rates were significantly increased in cells transfected with the PTGIS p.E314X variant-encoding construct when compared with that in cells transfected with the wild-type PTGIS-encoding construct. p.E314X reduced the tube formation ability in human pulmonary artery endothelial cells and caspase 3/7 activity in both human pulmonary artery endothelial cells and human pulmonary artery smooth muscle cells. Compared with healthy controls, patients with PPS exhibited downregulated pulmonary artery endothelial prostaglandin I2 synthase levels and urinary prostaglandin I metabolite levels. We identified another PTGIS rare splice-site variant (c.1358+2T>C) in another pediatric patient with WS and severe PPS. CONCLUSIONS: In total, 2 rare nonsense/splice-site PTGIS variants were identified in 2 pediatric patients with WS and severe PPS. PTGIS variants may be involved in PPS pathogenesis, and PTGIS represents an effective therapeutic target.
  • Tricuspid stenosis due to pectus excavatum in a paediatric patient with trisomy 21.
    Yuya Fujita; Ayako Chida-Nagai; Atsuhito Takeda
    European heart journal. Case reports, 8, 3, ytae104, 2024年03月, [査読有り], [国際誌]
    英語
  • Functional characterization of variants found in Japanese patients with hereditary hemorrhagic telangiectasia.
    Shuhei Morita; Shunsuke Nomura; Kenko Azuma; Ayako Chida-Nagai; Yoshiyuki Furutani; Kei Inai; Tatsuya Inoue; Yasunari Niimi; Yuo Iizuka; Yoshiyuki Tsutsumi; Reina Ishizaki; Hiroyuki Yamagishi; Takakazu Kawamata; Hiroyuki Akagawa
    Clinical genetics, 105, 5, 1, 6, 2024年01月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant form of vascular dysplasia. Genetic diagnosis is made by identifying loss-of-function variants in genes, such as ENG and ACVRL1. However, the causal mechanisms of various variants of unknown significance remains unclear. In this study, we analyzed 12 Japanese patients from 11 families who were clinically diagnosed with HHT. Sequencing analysis identified 11 distinct variants in ACVRL1 and ENG. Three of the 11 were truncating variants, leading to a definitive diagnosis, whereas the remaining eight were splice-site and missense variants that required functional analyses. In silico splicing analyses demonstrated that three variants, c.526-3C > G and c.598C > G in ACVRL1, and c.690-1G > A in ENG, caused aberrant splicing, as confirmed by a minigene assay. The five remaining missense variants were p.Arg67Gln, p.Ile256Asn, p.Leu285Pro, and p.Pro424Leu in ACVRL and p.Pro165His in ENG. Nanoluciferase-based bioluminescence analyses demonstrated that these ACVRL1 variants impaired cell membrane trafficking, resulting in the loss of bone morphogenetic protein 9 (BMP9) signal transduction. In contrast, the ENG mutation impaired BMP9 signaling despite normal cell membrane expression. The updated functional analysis methods performed in this study will facilitate effective genetic testing and appropriate medical care for patients with HHT.
  • A Noonan-like pediatric patient with a de novo CBL pathogenic variant and an RNF213 polymorphism p.R4810K presenting with cardiopulmonary arrest due to left main coronary artery ostial atresia.
    Ayako Chida-Nagai; Hidefumi Tonoki; Naomasa Makita; Hiroyuki Ishiyama; Masafumi Ihara; Yuji Maruo; Takao Tsujioka; Daisuke Sasaki; Gaku Izumi; Hirokuni Yamazawa; Nobuyasu Kato; Masaki Ito; Miki Fujimura; Osamu Sasaki; Atsuhito Takeda
    American journal of medical genetics. Part A, 191, 12, 2837, 2842, 2023年12月, [査読有り], [国際誌]
    英語, Left main coronary artery ostial atresia (LMCAOA) is an extremely rare condition. Here, we report the case of a 14-year-old boy with Noonan syndrome-like disorder in whom LMCAOA was detected following cardiopulmonary arrest. The patient had been diagnosed with Noonan syndrome-like disorder with a pathogenic splice site variant of CBL c.1228-2 A > G. He suddenly collapsed when he was running. After administering two electric shocks using an automated external defibrillator, the patient's heartbeat resumed. Cardiac catheterization confirmed the diagnosis of LMCAOA. Left main coronary artery angioplasty was performed. The patient was discharged without neurological sequelae. Brain magnetic resonance imaging revealed asymptomatic Moyamoya disease. In addition, RNF213 c.14429 G > A p.R4810K was identified. There are no reports on congenital coronary malformations of compound variations of RNF213 and CBL. In contrast, the RNF213 p.R4810K polymorphism has been established as a risk factor for angina pectoris and myocardial infarction in adults, and several congenital coronary malformations due to genetic abnormalities within the RAS/MAPK signaling pathway have been reported. This report aims to highlight the risk of sudden death in patients with RASopathy and RNF213 p.R4810K polymorphism and emphasize the significance of actively searching for coronary artery morphological abnormalities in these patients.
  • 肺高血圧症の遺伝学的背景に関する最近の話題
    永井礼子
    日本小児循環器学会雑誌, 39, 2, 62, 68, 2023年09月, [査読有り], [招待有り], [国内誌]
  • 我が国における小児特発性/遺伝性肺動脈性肺高血圧症(IPAH/HPAH)患者の治療の現状 Japan PH Registry(JAPHR)
    細川 奨; 石井 卓; 永井 礼子; 内田 敬子; 石田 秀和; 小垣 滋豊; 山岸 敬幸; 土井 庄三郎
    日本小児循環器学会総会・学術集会抄録集, 59回, [I, 05], (NPO)日本小児循環器学会, 2023年07月
    日本語
  • 小児心筋症診療の最先端 小児心筋症における心臓突然死の予防
    山澤 弘州; 武田 充人; 永井 礼子; 佐々木 大輔; 高畑 明日香
    日本小児循環器学会総会・学術集会抄録集, 59回, [III, 03], (NPO)日本小児循環器学会, 2023年07月
    英語
  • 左冠動脈口閉鎖症による心肺停止を呈した、RNF213 p.R4810K多型とCBL病的バリアントの両方を有する小児例
    永井 礼子; 佐々木 理; 丸尾 優爾; 辻岡 孝郎; 佐々木 大輔; 泉 岳; 山澤 弘州; 加藤 伸康; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 59回, [I, 02], (NPO)日本小児循環器学会, 2023年07月
    日本語
  • 当院における先天性左冠動脈開口部閉鎖と診断された5症例の臨床経過
    佐々木 大輔; 丸尾 優爾; 辻岡 孝郎; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 59回, [I, 05], (NPO)日本小児循環器学会, 2023年07月
    日本語
  • アンギオテンシン変換酵素阻害薬およびβ遮断薬の高用量使用が有効であった乳児の拡張型心筋症4症例の検討
    丸尾 優爾; 辻岡 孝郎; 佐々木 大輔; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 59回, [III, 08], (NPO)日本小児循環器学会, 2023年07月
    日本語
  • A case of infantile Barth syndrome with severe heart failure: Importance of splicing variants in the TAZ gene.
    Atsuhito Takeda; Masahiro Ueki; Jiro Abe; Kazuhiro Maeta; Tomoko Horiguchi; Hirokuni Yamazawa; Gaku Izumi; Ayako Chida-Nagai; Daisuke Sasaki; Takao Tsujioka; Itsumi Sato; Masahiro Shiraishi; Masafumi Matsuo
    Molecular genetics & genomic medicine, 11, 7, e2190, 2023年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Barth syndrome (BTHS) is an X-linked disorder characterized by cardiomyopathy, skeletal myopathy, and 3-methylglutaconic aciduria. The causative pathogenic variants for BTHS are in TAZ, which encodes a putative acyltransferase named tafazzin and is involved in the remodeling of cardiolipin in the inner mitochondrial membranes. Pathogenic variants in TAZ result in mitochondrial structural and functional abnormalities. We report a case of infantile BTHS with severe heart failure, left ventricular noncompaction, and lactic acidosis, having a missense c.640C>T (p.His214Tyr) variant in TAZ, which is considered a pathogenic variant based on the previously reported amino acid substitution at the same site (c.641A>G, p.His214Arg). However, in this previously reported case, heart function was compensated and not entirely similar to the present case. Silico prediction analysis suggested that c.640C>T could alter the TAZ messenger RNA (mRNA) splicing process. TAZ mRNAs in isolated peripheral mononuclear cells from the patient and in vitro splicing analysis using minigenes of TAZ found an 8 bp deletion at the 3' end of exon 8, which resulted in the formation of a termination codon in the coding region of exon 9 (H214Nfs*3). These findings suggest that splicing abnormalities should always be considered in BTHS.
  • 高感度トロポニンに潜むpitfall(The pitfall of cardiac troponin)
    山澤 弘州; 武田 充人; 永井 礼子; 佐々木 大輔; 辻岡 孝郎; 丸尾 優爾
    日本小児科学会雑誌, 127, 2, 345, 345, (公社)日本小児科学会, 2023年02月
    英語
  • Use of the index of pulmonary vascular disease for predicting long-term outcome of pulmonary arterial hypertension associated with congenital heart disease.
    Ayako Chida-Nagai; Naoki Masaki; Kay Maeda; Konosuke Sasaki; Hiroki Sato; Jun Muneuchi; Yoshie Ochiai; Hiroomi Murayama; Masahiro Tahara; Atsuko Shiono; Atsushi Shinozuka; Fumihiko Kono; Daisuke Machida; Shinichi Toyooka; Seiichiro Sugimoto; Kazufumi Nakamura; Satoshi Akagi; Maiko Kondo; Shingo Kasahara; Yasuhiro Kotani; Junichi Koizumi; Katsuhiko Oda; Masako Harada; Daisuke Nakajima; Akira Murata; Hazumu Nagata; Koichi Yatsunami; Tomio Kobayashi; Yoshikiyo Matsunaga; Takahiro Inoue; Hiroyuki Yamagishi; Naomi Nakagawa; Katsuki Ohtani; Masaki Yamamoto; Yushi Ito; Tatsunori Hokosaki; Yuta Kuwahara; Satoshi Masutani; Koji Nomura; Tsutomu Wada; Hirofumi Sawada; Masayuki Abiko; Tatsunori Takahashi; Yuichi Ishikawa; Seigo Okada; Atsushi Naitoh; Takako Toda; Tatsuya Ando; Akihiro Masuzawa; Shinsuke Hoshino; Masaaki Kawada; Yuichi Nomura; Kentaro Ueno; Naoki Ohashi; Tsuyoshi Tachibana; Yuchen Cao; Hideaki Ueda; Sadamitsu Yanagi; Masaaki Koide; Norie Mitsushita; Kouji Higashi; Yoshihiro Minosaki; Tomohiro Hayashi; Takashi Okamoto; Kenji Kuraishi; Eiji Ehara; Hidekazu Ishida; Hitoshi Horigome; Takashi Murakami; Kohta Takei; Taku Ishii; Gen Harada; Yasutaka Hirata; Jun Maeda; Shunsuke Tatebe; Chiharu Ota; Yasunobu Hayabuchi; Hisanori Sakazaki; Takashi Sasaki; Keiichi Hirono; Sayo Suzuki; Masahiro Yasuda; Atsuhito Takeda; Madoka Sawai; Kagami Miyaji; Atsushi Kitagawa; Yosuke Nakai; Nobuyuki Kakimoto; Kouta Agematsu; Atsushi Manabe; Yoshikatsu Saiki
    Frontiers in cardiovascular medicine, 10, 1212882, 1212882, 2023年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Limited data exist on risk factors for the long-term outcome of pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD-PAH). We focused on the index of pulmonary vascular disease (IPVD), an assessment system for pulmonary artery pathology specimens. The IPVD classifies pulmonary vascular lesions into four categories based on severity: (1) no intimal thickening, (2) cellular thickening of the intima, (3) fibrous thickening of the intima, and (4) destruction of the tunica media, with the overall grade expressed as an additive mean of these scores. This study aimed to investigate the relationship between IPVD and the long-term outcome of CHD-PAH. METHODS: This retrospective study examined lung pathology images of 764 patients with CHD-PAH aged <20 years whose lung specimens were submitted to the Japanese Research Institute of Pulmonary Vasculature for pulmonary pathological review between 2001 and 2020. Clinical information was collected retrospectively by each attending physician. The primary endpoint was cardiovascular death. RESULTS: The 5-year, 10-year, 15-year, and 20-year cardiovascular death-free survival rates for all patients were 92.0%, 90.4%, 87.3%, and 86.1%, respectively. The group with an IPVD of ≥2.0 had significantly poorer survival than the group with an IPVD <2.0 (P = .037). The Cox proportional hazards model adjusted for the presence of congenital anomaly syndromes associated with pulmonary hypertension, and age at lung biopsy showed similar results (hazard ratio 4.46; 95% confidence interval: 1.45-13.73; P = .009). CONCLUSIONS: The IPVD scoring system is useful for predicting the long-term outcome of CHD-PAH. For patients with an IPVD of ≥2.0, treatment strategies, including choosing palliative procedures such as pulmonary artery banding to restrict pulmonary blood flow and postponement of intracardiac repair, should be more carefully considered.
  • A Cardiac Arrest Case due to Left Coronary Artery Compression in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.
    Ayako Chida-Nagai; Ichizo Tsujino; Satoshi Yakuwa; Hiroyuki Akagawa; Takao Tsujioka; Kota Taniguchi; Osamu Sasaki; Gaku Izumi; Hirokuni Yamazawa; Atsuhito Takeda
    CJC pediatric and congenital heart disease, 1, 5, 229, 231, Elsevier BV, 2022年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We report the case of an adult who had a cardiac arrest in the setting of pulmonary hypertension and a previously repaired intermediate atrioventricular septal defect, with left main coronary trunk stenosis due to dilatation of the main pulmonary artery. In patients with pulmonary hypertension exhibiting anginal symptoms, it is advisable to perform chest contrast computed tomography to confirm the pulmonary artery diameter and the presence of coronary artery compression. In addition, our case highlights the importance of early collaboration among specialists during the transition from adolescence to adulthood.
  • Usefulness of Prolonged PR Interval to Predict Atrial Tachyarrhythmia Development Following Surgical Repair of Tetralogy of Fallot.
    Gaku Izumi; Atsuhito Takeda; Hirokuni Yamazawa; Ayako Nagai; Daisuke Sasaki; Itsumi Sato; Nobuyasu Kato; Tsuyoshi Tachibana
    The American journal of cardiology, 184, 127, 132, 2022年09月17日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Atrial tachyarrhythmias (ATAs), which may occur after tetralogy of Fallot (TOF) surgery, can cause sudden cardiac death. However, ATAs may also develop in response to electrical substrates. This study aims to examine the predictive factors for ATAs by identifying electrical substrates in the atrium obtained from 12-lead electrocardiogram in patients who underwent TOF repair. A total of 144 patients aged >15 years (median, 31.6 years) who underwent TOF repair at Hokkaido University were enrolled. We investigated the correlation between the development of ATAs with age, time interval after initial corrective surgery, brain natriuretic peptide levels, cardiac magnetic resonance parameters (right ventricular end-diastolic volume index, right ventricular end-systolic volume index, right ventricular ejection fraction, right atrial volume index, left ventricular end-diastolic volume index, left ventricular ejection fraction), and 12-lead electrocardiogram parameters (P wave maximum voltage, PR interval, QRS width, number of fragmented QRS). Of the 144 patients, 44 patients (30.6%) developed ATAs. Multivariate analysis revealed time interval after initial corrective surgery (odds ratio 6.7, 95% confidence interval 1.78 to 12.6) and PR interval (odds ratio 2.7, 95% confidence interval: 1.17 to 4.20) as independent risk factors for the development of ATAs. The receiver operating characteristic curve revealed a PR interval cut-off value of >200 milliseconds as predictive of the development of ATAs in patients more than 15 years after initial corrective surgery (area under the curve, 0.658; sensitivity, 71.4%; specificity, 66.4%). The present study demonstrated that a prolonged PR interval is a simple and convenient predictor for the development of ATAs in patients who underwent TOF repair.
  • 胎児診断を行ったCantrell症候群の臨床経験
    佐々木 大輔; 辻岡 孝郎; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人; 稗田 哲也; 加藤 伸康; 佐々木 理
    日本小児循環器学会総会・学術集会抄録集, 58回, [I, 03], (NPO)日本小児循環器学会, 2022年07月
    日本語
  • 主肺動脈拡張による左冠動脈主幹部圧排、心肺停止をきたした、先天性心疾患術後・肺動脈性肺高血圧症の成人例
    永井 礼子; 辻野 一三; 八鍬 聡; 辻岡 孝郎; 谷口 宏太; 佐々木 理; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 58回, [I, 08], (NPO)日本小児循環器学会, 2022年07月
    日本語
  • 頻脈性不整脈によって急性腎障害を発症した腎性低尿酸血症の1例
    辻岡 孝郎; 泉 岳; 信太 知; 岡本 孝之; 武田 充人; 山澤 弘州; 永井 礼子; 佐々木 大輔; 河村 優輔; 中山 昌喜; 松尾 洋孝
    日本小児循環器学会総会・学術集会抄録集, 58回, [III, 05], (NPO)日本小児循環器学会, 2022年07月
    日本語
  • 僧帽弁形成術後12年経過し良好な経過が得られている乳児マルファン症候群の一例
    佐藤 逸美; 白石 真大; 辻岡 孝郎; 佐々木 大輔; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 58回, [III, 07], (NPO)日本小児循環器学会, 2022年07月
    日本語
  • An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report.
    Ayako Chida-Nagai; Takao Tsujioka; Daisuke Sasaki; Gaku Izumi; Hirokuni Yamazawa; Atsuhito Takeda
    Frontiers in pediatrics, 10, 909595, 909595, 2022年06月, [査読有り], [国際誌]
    英語, Idiopathic pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting the pulmonary arteries. Epoprostenol, a synthetic prostaglandin analog, is the most potent pharmacological treatment modality used in patients with PAH. However, it requires continuous intravenous infusion, which negatively impacts the patient's quality of life and frequently results in complications, such as catheter-related bloodstream infection. We weaned an adolescent female patient off epoprostenol by gradually introducing oral selexipag over a sustained period, following many years of continuous intravenous epoprostenol use alone. Oral selexipag might have an efficacy comparable to epoprostenol in young patients with PAH.
  • 北海道における成人先天性心疾患の移行医療からみえてくるもの
    武田 充人; 山澤 弘州; 泉 岳; 佐々木 大輔; 永井 礼子; 辻岡 孝郎; 真部 淳
    小児保健研究, 81, 講演集, 134, 134, (公社)日本小児保健協会, 2022年05月
    日本語
  • COVID-19ワクチン関連心筋炎と考えられる1例(Association of Myocarditis with mRNA COVID-19 Vaccine in a case of children)
    山澤 弘州; 武田 充人; 泉 岳; 永井 礼子; 佐々木 大輔; 佐藤 逸美
    日本小児科学会雑誌, 126, 2, 321, 321, (公社)日本小児科学会, 2022年02月
    英語
  • Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
    Ayako Chida-Nagai; Hiroki Sato; Itsumi Sato; Masahiro Shiraishi; Daisuke Sasaki; Gaku Izumi; Hirokuni Yamazawa; Kazutoshi Cho; Atsushi Manabe; Atsuhito Takeda
    European journal of pediatrics, 181, 2, 539, 547, Springer Science and Business Media LLC, 2022年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Respiratory syncytial virus (RSV) is a common pathogen that causes extremely severe respiratory symptoms in the first few weeks and months of life. In infants with cardiopulmonary diseases, RSV infections have a significant clinical impact. Palivizumab, a humanised monoclonal antibody for RSV, has been shown to significantly reduce the rate of hospitalisation of high-risk infants diagnosed with RSV. However, we have experienced a significant number of RSV infections in our institution that required hospitalisation or intensive care, despite the administration of palivizumab. This study aimed to analyse the risk factors associated with severe RSV despite the use of palivizumab. We retrospectively reviewed the medical records of 688 patients who visited or were admitted to our hospital and received palivizumab. Thirty-seven (5.4%) patients required hospitalisation for RSV, despite receiving palivizumab. In addition, 31 of these patients (83.8%) required hospitalisation out of season for palivizumab injection. Preterm birth (≤ 28-week gestation), bronchopulmonary dysplasia (BPD), and trisomy 21 were risk factors for RSV-related hospitalisation in infected patients, despite receiving palivizumab. Furthermore, subgroup analysis of 69 patients with RSV revealed that hemodynamically significant congenital heart disease (CHD) was also a risk factor for RSV-related hospitalisation.Conclusion: Preterm birth (≤ 28 weeks of gestation), BPD, trisomy 21, hemodynamically significant CHD, and CHD requiring surgery or cardiac catheterisation/intervention during infancy could be considered when determining whether year-round administration of palivizumab is appropriate. What is Known: • Respiratory syncytial virus causes severe respiratory symptoms in infants, particularly those with cardiopulmonary diseases. • The use of palivizumab has reduced the rate of hospitalisation of infants diagnosed with RSV. Despite this, the rate of hospitalisation is still high. What is New: • We identified that preterm birth (≤ 28-week gestation), bronchopulmonary dysplasia, trisomy 21, and hemodynamically significant congenital heart disease were risk factors for RSV-related hospitalisation, even after receiving palivizumab treatment. • High-risk infants should be closely monitored and the prolonged use of palivizumab should be considered.
  • Left ventricular inflow obstruction due to a coronary arteriovenous fistula: a paediatric case report.
    Ayako Chida-Nagai; Hirokuni Yamazawa; Takao Tsujioka; Kota Taniguchi; Osamu Sasaki; Gaku Izumi; Nobuyasu Kato; Atsuhito Takeda
    BMC cardiovascular disorders, 21, 1, 389, 389, 2021年08月11日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: We report a rare case of left ventricular inflow obstruction from a branch of the left circumflex coronary artery to the right atrium caused by a coronary arteriovenous fistula (CAVF) in a young Japanese male child. CASE PRESENTATION: The patient was diagnosed with CAVF following a heart murmur shortly after birth. The left-to-right shunt caused right ventricular volume overload and pulmonary congestion. An emergency surgical intervention was performed for the CAVF on day 6 after birth. However, by 5 years of age, his left ventricular inflow obstruction worsened. We found an abnormal blood vessel originating from the proximal part of a branch of the left circumflex coronary artery, circling the outside of the mitral valve annulus along the medial side of the coronary sinus. As the child gets older, the blood inflow into the left ventricle might get restricted further, resulting in left-sided heart failure. CONCLUSION: Our findings suggest that even after CAVF closure surgery, it is essential to monitor for complications caused by progressive dilatation of a persistent CAVF.
  • 小児循環器領域のゲノム医学 重症多発性末梢性肺動脈狭窄症におけるX遺伝子変異の意義
    永井 礼子; 澤井 彩織; 八鍬 聡; 赤川 浩之; 古谷 喜幸; 高桑 恵美; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 57回, [I, 2], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 小児肥大型心筋症に対するシベンゾリンの効果
    山澤 弘州; 武田 充人; 泉 岳; 永井 礼子; 佐々木 大輔; 辻岡 孝郎; 白石 真大; 佐藤 逸美
    日本小児循環器学会総会・学術集会抄録集, 57回, [OR19, 1], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • ファロー四徴症術後のPQ時間延長は頻脈性心房性不整脈発症の予測因子となる
    泉 岳; 武田 充人; 山澤 弘州; 永井 礼子; 佐々木 大輔; 佐藤 逸美; 加藤 伸康
    日本小児循環器学会総会・学術集会抄録集, 57回, [OR26, 2], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 先天性心疾患術後から乳び胸管理に難渋しリンパ管造影を実施したヌーナン症候群の乳児例
    佐藤 逸美; 白石 真大; 辻岡 孝郎; 佐々木 大輔; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 57回, [P32, 2], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 小児心不全予後のsurrogate markerを考える 先天性僧帽弁閉鎖不全症における術前のpredictive Wall Stressは術後遠隔期左室機能のsurrogate markerとなりうるか
    白石 真大; 村上 智明; 佐藤 逸美; 辻岡 孝郎; 佐々木 大輔; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 57回, [I, 3], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 小児心不全予後のsurrogate markerを考える 先天性僧帽弁閉鎖不全症における術前のpredictive Wall Stressは術後遠隔期左室機能のsurrogate markerとなりうるか
    白石 真大; 村上 智明; 佐藤 逸美; 辻岡 孝郎; 佐々木 大輔; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 57回, [I, 3], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 小児肥大型心筋症に対するシベンゾリンの効果
    山澤 弘州; 武田 充人; 泉 岳; 永井 礼子; 佐々木 大輔; 辻岡 孝郎; 白石 真大; 佐藤 逸美
    日本小児循環器学会総会・学術集会抄録集, 57回, [OR19, 1], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • ファロー四徴症術後のPQ時間延長は頻脈性心房性不整脈発症の予測因子となる
    泉 岳; 武田 充人; 山澤 弘州; 永井 礼子; 佐々木 大輔; 佐藤 逸美; 加藤 伸康
    日本小児循環器学会総会・学術集会抄録集, 57回, [OR26, 2], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 先天性心疾患術後から乳び胸管理に難渋しリンパ管造影を実施したヌーナン症候群の乳児例
    佐藤 逸美; 白石 真大; 辻岡 孝郎; 佐々木 大輔; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会総会・学術集会抄録集, 57回, [P32, 2], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 肺高血圧症における基礎研究の最近の話題:分子遺伝学的背景を中心に
    永井礼子
    日本小児循環器学会雑誌, 37, 1, 2, 9, 2021年04月, [査読有り], [国内誌]
  • 先天性心疾患術後から乳び胸管理に難渋しリンパ管造影を実施したヌーナン症候群の乳児例
    佐藤 逸美; 白石 真大; 佐々木 大輔; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人; 真部 淳
    日本小児科学会雑誌, 125, 2, 318, 318, (公社)日本小児科学会, 2021年02月
    日本語
  • Total Anomalous Pulmonary Venous Connection with Lethal Pulmonary Venous Obstruction Managed by Multidisciplinary Cooperation
    Kana Ito; Ayako Chida-Nagai; Osamu Sasaki; Nobuyasu Kato; Takeshi Umazume; Satoshi Kawaguchi; Kazutoshi Cho; Gaku Izumi; Hirokuni Yamazawa; Atsuhito Takeda
    Case Reports in Pediatrics, 2021, 1, 5, Hindawi Limited, 2021年01月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background. Total anomalous pulmonary venous connection (TAPVC) is a critical congenital heart disease for which emergency surgery is required after birth. In cases of no intervention, TAPVC is associated with a high mortality rate in the first year of life. Although foetal echocardiographic techniques for diagnosing TAPVC have improved, TAPVC remains one of the most difficult congenital heart diseases to diagnose via foetal echocardiography. Here, we report a case of TAPVC with pulmonary venous obstruction (PVO), which was diagnosed via foetal echocardiography. Case Presentation. On foetal echocardiography at 32 weeks’ gestation, a large atrial septal defect, enlarged superior vena cava, and continuous flow pattern in the vertical vein from the common chamber were observed in the foetus. Paediatric cardiologists and cardiac surgeons, neonatologists, and obstetricians planned to perform a caesarean section and emergency heart surgery. The male infant was born at 37 weeks’ gestation via caesarean section, and postnatal echocardiography revealed PVO at the confluence of the superior vena cava and common chamber. Similarly, chest computed tomography confirmed the foetal diagnosis. The postnatal diagnoses were TAPVC type Ib, PVO, atrial septal defect, and patent ductus arteriosus. Surgical repair of the TAPVC was initiated within the first 3 hours of life. Screening brain echocardiography and head computed tomography revealed intracranial haemorrhage and hydrocephalus. Therefore, the patient underwent emergency bilateral external drainage on day 13. On day 48, a ventriculoperitoneal shunt was inserted owing to progressive brain ventricular dilatation. The patient was discharged home on postoperative day 68. Conclusions. Although the prognosis of TAPVC with PVO remains poor, continuous observation through foetal echocardiography and early interdepartmental collaboration can result in good outcomes.
  • A case report: Twin sisters with restrictive cardiomyopathy associated with rare mutations in the cardiac troponin I gene
    Michihiko Ueno; Atsuhito Takeda; Hirokuni Yamazawa; Kohta Takei; Takuo Furukawa; Yasuto Suzuki; Ayako Chida-Nagai; Akinori Kimura
    Journal of Cardiology Cases, 23, 4, 154, 157, 2020年12月, [査読有り], [国内誌]
    英語, Restrictive cardiomyopathy (RCM) is a rare cardiomyopathy in children, and its prognosis until now, has been poor. Recently some sarcomeric mutations have been reported as disease-causing genes of RCM. However, the genotype-phenotype correlation is not fully understood. Additionally, prognostic factors including sudden death in patients with RCM have not been elucidated. We report our experience in treating twin sisters with RCM or hypertrophic cardiomyopathy with RCM phenotype, both carriers of the same mutation in TNNI3, which encodes one of the major sarcomeric proteins in myofibrils. They were both diagnosed with RCM by cardiac catheterization at the age of 11 years. Despite appropriate follow-up and medical treatment, one died suddenly at the age of 11 years and the other also died at the age of 15 years due to heart failure while awaiting heart transplantation. In addition to our cases, other reports of younger fatal cases with RCM carrying TNNI3 mutations may suggest it as one of the prognostic factors. Genetic diagnosis is important in the clinical diagnosis, management, and treatment of cardiomyopathy. .
  • 6th World Symposium on PH2018を、どう解釈し、どう活かすべきか? "肺動脈性"肺高血圧症の境界線は、私達が想像していた以上に曖昧である PAH with overt features of PVOD/PCH involvement
    永井 礼子; 佐藤 逸美; 白石 真大; 佐々木 大輔; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 112, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • 先天性心疾患周術期接合部頻拍のリスク因子
    泉 岳; 武田 充人; 山澤 弘州; 永井 礼子; 阿部 二郎; 谷口 宏太; 加藤 伸康; 荒木 大
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 212, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • 小児肥大型心筋症の急激な壁厚増大は不整脈のリスク因子、新規リスクモデルの修飾因子となる可能性がある
    山澤 弘州; 武田 充人; 永井 礼子; 泉 岳; 阿部 二郎; 谷口 宏太; 佐々木 大輔; 辻岡 孝郎
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 218, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • 予防的DKS術後の大動脈弁逆流・旧肺動脈弁逆流に対する検討
    谷口 宏太; 永井 礼子; 阿部 次郎; 泉 岳; 山澤 弘州; 武田 充人; 加藤 伸康
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 246, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • 進行性の多発性末梢性肺動脈狭窄を呈し、対応に苦慮しているWilliams症候群の1例
    澤井 彩織; 永井 礼子; 谷口 宏太; 阿部 二郎; 泉 岳; 山澤 弘州; 八鍬 聡; 武田 充人
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 264, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • 胎児診断された先天性心疾患症例はどこで分娩するのが適切か?
    佐々木 理; 佐々木 大輔; 谷口 宏太; 阿部 二郎; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 267, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • 可逆性の肺高血圧症および右心不全を呈し、確定診断に苦慮した閉塞性睡眠時無呼吸症候群の幼児例
    白石 春生; 永井 礼子; 谷口 宏太; 阿部 二郎; 泉 岳; 山澤 弘州; 佐々木 理; 武田 充人
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 350, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • Diagnostic dilemma in a case of obstructive sleep apnoea syndrome with reversible pulmonary hypertension and right heart failure: A case report.
    Shiraishi H; Chida-Nagai A; Taniguchi K; Abe J; Izumi G; Yamazawa H; Ueda Y; Sasaki O; Miyakoshi K; Takeda A
    International Journal of Pediatric Otorhinolaryngology [Online ahead of print], 138, 110378, 110378, 2020年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Childhood obstructive sleep apnoea syndrome (OSAS) secondary to adenoid hyperplasia is known to give rise to pulmonary hypertension. However, we present a case of a toddler with pulmonary hypertension (PH) and right heart failure due to OSAS, the cause of which is difficult to identify. After the patient underwent an adenotonsillectomy, OSAS disappeared and the PH eventually resolved. Both paediatricians and otolaryngologists should know that paediatric OSAS can occur even in the setting of mild, clinically insignificant palatine tonsil hypertrophy and adenoid hyperplasia. Surgical intervention should be considered without losing the opportunity if it could be the cause of PH.
  • Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.
    Ayako Chida-Nagai; Koichi Sagawa; Takao Tsujioka; Takanori Fujimoto; Kota Taniguchi; Osamu Sasaki; Gaku Izumi; Hirokuni Yamazawa; Naoki Masaki; Atsushi Manabe; Atsuhito Takeda
    Heart and vessels, 35, 9, 1307, 1315, 2020年09月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) is one of the major complications in patients with CHD. A timely closure of the left-to-right shunt will generally result in the normalization of the pulmonary hemodynamics, but a few patients have severe prognosis in their early childhood. We hypothesized that wide-ranging pathological mechanism in PAH could elucidate the clinical state of severe CHD-PAH. Using electronic medical records, we retrospectively analyzed six infants with severe CHD-PAH who had treatment-resistant PH. All patients were born with congenital malformation syndrome. After starting on a pulmonary vasodilator, five of the six patients developed complications including pulmonary edema and interstitial lung disease (ILD), and four patients had alveolar hemorrhage. After steroid therapy, the clinical condition improved in four patients, but two patients died. The autopsy findings in one of the deceased patients indicated the presence of recurrent alveolar hemorrhage, pulmonary venous hypertension, ILD, and PAH. Based on the clinical course of these CHD-PAH in patients and the literature, CHD-PAH can occur with pulmonary vascular obstructive disease (PVOD)/pulmonary capillary hemangiomatosis (PCH), ILD, and/or alveolar hemorrhage. The severity of CHD-PAH may depend on a genetic disorder, respiratory infection, and upper airway stenosis. Additionally, pulmonary vasodilators may be involved in the development of PVOD/PCH and ILD. When patients with CHD-PAH show unexpected deterioration, clinicians should consider complications associated with PVOD/PCH and/or pulmonary disease. In addition, the choice of upfront combination therapy for pediatric patients with CHD-PAH should be selected carefully.
  • Advanced pathological study for definite diagnosis of mitochondrial cardiomyopathy.
    Atsuhito Takeda; Kei Murayama; Yasushi Okazaki; Atsuko Imai-Okazaki; Akira Ohtake; Emi Takakuwa; Hirokuni Yamazawa; Gaku Izumi; Jiro Abe; Ayako Nagai; Kota Taniguchi; Daisuke Sasaki; Takao Tsujioka; John M Basgen
    Journal of clinical pathology, 2020年08月17日, [査読有り], [国際共著], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Mitochondrial cardiomyopathy (MCM) is difficult to make a definite diagnosis because of various cardiovascular phenotypes and no diagnostic criteria in the pathology examination. We aim to add myocardial pathology to the diagnostic criteria for mitochondrial respiratory chain disorders. METHODS: Quantitative analysis of mitochondria using electron microscopy and immunohistopathological analysis with respiratory chain enzyme antibodies were performed in 11 patients with hypertrophic or restrictive cardiomyopathy who underwent endomyocardial biopsy for possible MCM . Respiratory chain enzymatic assay in biopsied myocardium and genetic studies were also performed in all the subjects to define MCM. RESULTS: Four patients were diagnosed with MCM according to the recent criteria of mitochondrial respiratory chain disorders. Using electron microscopy with quantitative analysis, the volume density of mitochondria within cardiac muscle cells was significantly increased in the MCM group compared with the non-MCM group (p=0.007). Immunohistopathological results were compatible with the result of the respiratory chain enzymatic assay. CONCLUSIONS: Pathological diagnosis of MCM could be confirmed by a quantitative study of electron microscopy and immunohistopathological analysis using the mitochondrial respiratory chain enzyme subunit antibody.
  • 小児循環器領域における肺高血圧症:臨床と基礎のフロントライン
    永井 礼子
    日本小児循環器学会雑誌, 35, 3, 136, 152, 2019年10月, [査読有り], [国内誌]
  • Role of BRCA1-associated protein (BRAP) variant in childhood pulmonary arterial hypertension.
    Ayako Chida-Nagai; Masaki Shintani; Hiroki Sato; Tomotaka Nakayama; Masaki Nii; Hiroyuki Akagawa; Toru Furukawa; Amer Rana; Yoshiyuki Furutani; Kei Inai; Shigeaki Nonoyama; Toshio Nakanishi
    PloS one, 14, 1, e0211450, 2019年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Although mutations in several genes have been reported in pulmonary arterial hypertension (PAH), most of PAH cases do not carry these mutations. This study aimed to identify a novel cause of PAH. To determine the disease-causing variants, direct sequencing and multiplex ligation-dependent probe amplification were performed to analyze 18 families with multiple affected family members with PAH. In one of the 18 families with PAH, no disease-causing variants were found in any of BMPR2, ACVRL1, ENG, SMAD1/4/8, BMPR1B, NOTCH3, CAV1, or KCNK3. In this family, a female proband and her paternal aunt developed PAH in their childhood. Whole-exome next-generation sequencing was performed in the 2 PAH patients and the proband's healthy mother, and a BRCA1-associated protein (BRAP) gene variant, p.Arg554Leu, was identified in the 2 family members with PAH, but not in the proband's mother without PAH. Functional analyses were performed using human pulmonary arterial smooth muscle cells (hPASMCs). Knockdown of BRAP via small interfering RNA in hPASMCs induced p53 signaling pathway activation and decreased cell proliferation. Overexpression of either wild-type BRAP or p.Arg554Leu-BRAP cDNA constructs caused cell death confounding these studies, however we observed higher levels of p53 signaling inactivation and hPASMC proliferation in cells expressing p.Arg554Leu-BRAP compared to wild-type BRAP. In addition, p.Arg554Leu-BRAP induced decreased apoptosis of hPASMCs compared with wild-type BRAP. In conclusion, we have identified a novel variant of BRAP in a Japanese family with PAH and our results suggest it could have a gain-of-function. This study sheds light on new mechanism of PAH pathogenesis.
  • Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy
    Ayako Chida; Kei Inai; Hiroki Sato; Eriko Shimada; Tsutomu Nishizawa; Mitsuyo Shimada; Michiko Furutani; Yoshiyuki Furutani; Yoichi Kawamura; Masaya Sugimoto; Jun Ishihara; Masako Fujiwara; Takashi Soga; Masatoshi Kawana; Shinya Fuji; Shigeru Tateno; Kenji Kuraishi; Shigetoyo Kogaki; Mitsuhiro Nishimura; Mamoru Ayusawa; Fukiko Ichida; Hirokuni Yamazawa; Rumiko Matsuoka; Shigeaki Nonoyama; Toshio Nakanishi
    HEART AND VESSELS, 32, 6, 700, 707, 2017年06月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • 肺動脈性肺高血圧症における遺伝子異常
    千田 礼子
    日本小児科学会雑誌, 120, 9, 1295, 1307, (公社)日本小児科学会, 2016年09月, [査読有り], [国内誌]
    日本語, 小児期発症肺動脈性肺高血圧症(PAH)患者における遺伝子変異と予後との関係を検討した結果、BMPR2変異群は、既知の原因遺伝子変異を認めない群よりも明らかに予後が不良であり、ALK1変異群も予後不良な傾向にあった。小児期発症PAHにおける遺伝子変異と予後との関係、PAHの新規疾患原因遺伝子候補について概説し、最後にPAHにおいて原因遺伝子変異を検索する意義とその適応について述べた。
  • Mutations of NOTCH3 in childhood pulmonary arterial hypertension.
    Chida A; Shintani M; Matsushita Y; Sato H; Eitoku T; Nakayama T; Furutani Y; Hayama E; Kawamura Y; Inai K; Ohtsuki S; Saji T; Nonoyama S; Nakanishi T
    Molecular genetics & genomic medicine, 2, 3, 229, 239, 2014年05月, [査読有り], [国際誌]
  • Soluble ST2 and N-terminal pro-Brain Natriuretic Peptide Combination - Useful Biomarker for Predicting Outcome of Childhood Pulmonary Arterial Hypertension
    Ayako Chida; Hiroki Sato; Masaki Shintani; Tomotaka Nakayama; Yoichi Kawamura; Yoshiyuki Furutani; Kei Inai; Tsutomu Saji; Rumiko Matsuoka; Shigeaki Nonoyama; Toshio Nakanishi
    CIRCULATION JOURNAL, 78, 2, 436, 442, 2014年02月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Maternal mosaicism of an ANKH mutation in a family with craniometaphyseal dysplasia
    Tamaki Kato; Hiroshi Matsumoto; Ayako Chida; Hajime Wakamatsu; Shigeaki Nonoyama
    PEDIATRICS INTERNATIONAL, 55, 2, 254, 256, 2013年04月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • ACVRL1 gene variant in a patient with vein of galen aneurysmal malformation
    Ayako Chida; Masaki Shintani; Hajime Wakamatsu; Yoshiyuki Tsutsumi; Yuo Iizuka; Nanako Kawaguchi; Yoshiyuki Furutani; Kei Inai; Shigeaki Nonoyama; Toshio Nakanishi
    Journal of Pediatric Genetics, 2, 4, 181, 189, 2013年, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers
    Ayako Chida; Masaki Shintani; Hisato Yagi; Maya Fujiwara; Yasuko Kojima; Hiroki Sato; Shinichiro Imamura; Masato Yokozawa; Norio Onodera; Hitoshi Horigome; Tomio Kobayashi; Yoshiho Hatai; Tomotaka Nakayama; Hiroyuki Fukushima; Mitsunori Nishiyama; Shouzaburo Doi; Yasuo Ono; Satoshi Yasukouchi; Fukiko Ichida; Kazuto Fujimoto; Shinichi Ohtsuki; Hidetaka Teshima; Tatsuya Kawano; Yuichi Nomura; Hong Gu; Takahiro Ishiwata; Yoshiyuki Furutani; Kei Inai; Tsutomu Saji; Rumiko Matsuoka; Shigeaki Nonoyama; Toshio Nakanishi
    AMERICAN JOURNAL OF CARDIOLOGY, 110, 4, 586, 593, 2012年08月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Missense Mutations of the BMPR1B (ALK6) Gene in Childhood Idiopathic Pulmonary Arterial Hypertension
    Ayako Chida; Masaki Shintani; Tomotaka Nakayama; Yoshiyuki Furutani; Emiko Hayama; Kei Inai; Tsutomu Saji; Shigeaki Nonoyama; Toshio Nakanishi
    CIRCULATION JOURNAL, 76, 6, 1501, 1508, 2012年06月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • SEVERE HUMAN HERPESVIRUS 6-ASSOCIATED ENCEPHALOPATHY IN THREE CHILDREN ANALYSIS OF CYTOKINE PROFILES AND THE CARNITINE PALMITOYLTRANSFERASE 2 GENE
    Hiroshi Matsumoto; Daisuke Hatanaka; Yumi Ogura; Ayako Chida; Yasuko Nakamura; Shigeaki Nonoyama
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 30, 11, 999, 1001, 2011年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Cardiopulmonary Arrest Caused by Craniometaphyseal Dysplasia
    Ayako Chida; Youichi Yanagawa; Hiroshi Matsumoto; Shigeaki Nonoyama
    INDIAN JOURNAL OF PEDIATRICS, 78, 8, 1010, 1012, 2011年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Rapidly progressive encephalopathy with coagulation abnormality (Case Presentation)
    Ayako Chida; Hiroshi Matsumoto; Takako Asano; Shigeaki Nonoyama
    ACTA PAEDIATRICA, 99, 12, 1759, +, 2010年12月, [査読有り], [国際誌]
    英語
  • 乳児期に急性うっ血性心不全を呈する僧帽弁腱索断裂
    千田 礼子; 成田 純任; 石川 司朗; 石川 友一; 中村 真; 牛ノ濱 大也; 佐川 浩一; 角 秀秋
    心臓, 40, 4, 359, 364, (公財)日本心臓財団, 2008年04月, [査読有り], [国内誌]
    日本語
  • Dup(8p)/del(8q) recombinant chromosome in a girl with hepatic focal nodular hyperplasia
    Tomoharu Tokutomi; Shin Hayashi; Kohsuke Imai; Ayako Chida; Takahiro Ishiwata; Yuh Asano; Johji Inazawa; Shigeaki Nonoyama
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 143A, 12, 1334, 1337, 2007年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A non-obese boy with Prader-Willi syndrome shows cardiopulmonary impairment due to severe kyphoscoliosis
    Tomoharu Tokutomi; Ayako Chida; Yuh Asano; Takahiro Ishiwata; Yuji Koike; Akira Motegi; Takashi Asazuma; Shigeaki Nonoyama
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 140A, 18, 1978, 1980, 2006年09月, [査読有り], [国際誌]
    英語
  • 夏季におけるRSウイルスによる下気道感染症の3例
    千田 礼子; 磯崎 淳; 古池 雄治; 石井 茂樹; 黒木 康富; 藤塚 聡; 野々山 恵章
    防衛医科大学校雑誌, 30, 4, 188, 192, 防衛医科大学校雑誌編集委員会, 2005年12月, [国内誌]
    日本語, 症例1:1歳9ヵ月男児.発熱と喘息を主訴とした.胸部X線で両側の肺門から下肺野にかけて気管支陰影の増強を認め,ディレクティジュンEZ RSウイルス(RSV)を用いた鼻汁中RSV抗原の検出は陽性であった.β刺激薬の吸入とアミノフィリンの持続静脈内投与,および酸素投与を行い,軽度症状改善後は徐放型キサンチン製剤の内服に変更した.RSV抗体価は入院前4倍であったが退院後は32倍に上昇し,RSV感染症と診断した.症例2:2歳4ヵ月女児.発熱と咳嗽を主訴とした.1歳7ヵ月時にRSV感染による気管支肺炎の既往があった.胸部X線で肺門から肺野にかけて気管支陰影の増強を認め,ディレクティジュンEZ RSVを用いた鼻汁中RSV抗原の検出は陽性であった.また,低酸素血症も認めた.酸素テントに収容し,輸液を行い,喘鳴は認めなかったがβ刺激薬の吸入を併用した.徐々に症状は改善し退院した.RSV抗体価は入院前64倍であったが退院後は256倍に上昇し,RSV感染症と診断した.症例3:2ヵ月男児.咳嗽を主訴とした.RSV抗原陽性で,胸部X線では軽度の気腫性変化を認めた.また,低酸素血症も認めた.酸素テントに収容し,輸液を行い,症状改善したため退院した
  • マムシ咬傷とその初療について 重症例2例の経験を通して
    金子 直之; 千田 礼子; 岡田 芳明
    日本臨床救急医学会雑誌, 8, 5, 378, 384, (一社)日本臨床救急医学会, 2005年10月, [査読有り], [国内誌]
    日本語
■ その他活動・業績
  • 「心不全診療の未来戦略」遺伝学的視点から迫る肺動脈性肺高血圧症-発症機序の解明と治療革新
    永井 礼子, 医学のあゆみ, 295, 9, 760, 764, 2025年11月
  • 先天性門脈体循環シャント(CPSS)の全国調査:肺高血圧症合併患者の特徴と予後
    松岡良平; 石田秀和; 井福俊允; 大橋啓之; 永井礼子; 原卓也; 廣野恵一; 前田潤; 宗内淳; 村上卓; 永田弾, 日本小児循環器学会総会・学術集会(Web), 61st, 2025年
  • 心室中隔欠損症,肺動脈閉鎖症および主要大動脈肺動脈側副血管における肺高血圧症治療の適用に関する系統的レビュー
    廣野恵一; 内田敬子; 永井礼子; 細川奨; 石井卓; 高月晋一; 石田秀和; 山岸敬幸; 土井庄三郎; 小垣滋豊, 日本小児循環器学会総会・学術集会(Web), 61st, 2025年
  • 小児期発症IPAH/HPAHに対する治療-JAPHRと自験例から見える現状
    住友直文; 細川奨; 石井卓; 林立申; 永井礼子; 石田秀和; 内田敬子; 福島裕之; 土井庄三郎; 土井庄三郎; 山岸敬幸; 山岸敬幸, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年
  • 完全把握をめざす小児の心疾患「肺高血圧症」
    永井 礼子, 小児内科, 2024年04月
  • 「房室中隔欠損(心内膜床欠損)」「動脈管開存症」「エプスタイン病」
    永井 礼子, 「最新の臨床WEB」南江堂, 2024年04月
  • 我が国の小児特発性/遺伝性肺動脈性肺高血圧症患者の治療の現状
    細川奨; 細川奨; 石井卓; 永井礼子; 内田敬子; 内田敬子; 石田秀和; 小垣滋豊; 山岸敬幸; 山岸敬幸; 土井庄三郎; 土井庄三郎, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 9th (CD-ROM), 2024年
  • 先天性心疾患とRNF213バリアントの両方を有する,重症肺動脈性肺高血圧症の一例
    永井礼子; 辻野一三; 八鍬聡; 赤川浩之; 辻岡孝郎; 谷口宏太; 佐々木理; 泉岳; 山澤弘州; 武田充人, 日本人類遺伝学会大会(CD-ROM), 67th, 2022年
  • 先天性心疾患に伴う肺高血圧症と遺伝学的特性
    永井 礼子, Pulmonary Hypertension Update, 7, 2, 38, 42, 2021年12月
  • 小児遺伝子疾患辞典:BMPR2
    永井 礼子, 小児科診療, 84, 11, 1585, 1589, 2021年10月, [査読有り], [招待有り]
  • 重症肺動脈性肺高血圧症の病態と新規治療法の開発
    永井 礼子, Medical Science Digest, 2020年12月
  • 急性骨髄性白血病(AML)治療後で高度肺高血圧と心機能低下を伴った心室中隔欠損(VSD)のダウン症候群(DS)乳児例の治療経験 手術にむけての内科管理について
    野上 正雄; 上野 倫彦; 長谷山 圭司; 南雲 淳; 黒江 俊秀; 奥村 遼; 松元 献; 荒井 勇人; 和田 宗一郎; 及川 純子; 大谷 杏奈; 田村 卓也; 齋 秀二; 那須 敬; 岩田 正道; 辻岡 孝郎; 佐々木 大輔; 永井 礼子; 谷口 宏太; 阿部 二郎; 泉 岳; 山澤 弘州; 武田 充人; 堀 大紀; 松島 悟; 柳 将人; 小玉 浩弥; 鈴木 大介; 小林 良二; 小林 邦彦, 日本小児科学会雑誌, 124, 8, 1309, 1309, 2020年08月
    (公社)日本小児科学会, 日本語
  • 当院で管理中の先天性門脈体循環シャント6例の検討
    辻岡 孝郎; 泉 岳; 武田 充人; 小杉山 清隆; 山澤 弘州; 阿部 二郎; 谷口 宏太; 佐々木 大輔; 永井 礼子; 本多 昌平; 荒 桃子; 阿保 大介; 曽山 武士; 川村 典生; 渡辺 正明; 後藤 了一; 嶋村 剛; 神山 俊哉; 武冨 紹信; 真部 淳, 日本小児科学会雑誌, 124, 2, 250, 250, 2020年02月
    (公社)日本小児科学会, 日本語
  • 【小児循環器領域の生涯包括遺伝医療】疾患各論 肺高血圧症の遺伝学
    永井 礼子, 小児科診療, 82, 7, 946, 952, 2019年07月, [招待有り]
    (株)診断と治療社, 日本語
  • 不整脈カテーテルアブレーション:治療困難症例に対する戦略 Fontan術後心房頻拍に対するアブレーション成功部位の電位的特徴
    泉 岳; 武田 充人; 山澤 弘州; 佐々木 理; 谷口 宏太; 佐々木 大輔; 藤本 隆憲; 辻岡 孝郎; 永井 礼子; 加藤 伸康; 新井 洋輔, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 121, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 体肺血管抵抗バランスの崩れたFontan患者における神経体液性因子の反応
    泉 岳; 山澤 弘州; 武田 充人; 佐々木 理; 谷口 宏太; 佐々木 大輔; 藤本 隆憲; 辻岡 孝郎; 永井 礼子; 加藤 伸康; 新井 洋輔, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 196, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 北海道における先天性心疾患の胎児診断の有用性
    佐々木 理; 藤本 隆憲; 辻岡 孝郎; 谷口 宏太; 永井 礼子; 泉 岳; 山澤 弘州; 武田 充人, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 198, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 21trisomy合併左右短絡心疾患児の肺血流予測因子の検討
    藤本 隆憲; 山澤 弘州; 泉 岳; 佐々木 理; 谷口 宏太; 辻岡 孝郎; 永井 礼子; 佐々木 大輔; 武田 充人, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 200, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 修正大血管転位における肺動脈絞扼術の成績とDouble Switch Operationの要否
    谷口 宏太; 武田 充人; 辻岡 孝郎; 藤本 隆憲; 永井 礼子; 佐々木 理; 泉 岳; 山澤 弘州; 加藤 伸康; 橘 剛, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 222, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 若年肥大型心筋症の突然死リスクを見直す
    山澤 弘州; 武田 充人; 泉 岳; 佐々木 理; 谷口 宏太; 永井 礼子; 藤本 隆憲; 辻岡 孝郎, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 281, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • フォンタン手術適応の大血管転位型心疾患に対する肺動脈絞扼術とBTシャント手術併用の有用性
    辻岡 孝郎; 藤本 隆憲; 谷口 宏太; 永井 礼子; 泉 岳; 佐々木 理; 山澤 弘州; 武田 充人; 新井 洋輔; 加藤 伸康; 橘 剛, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 347, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 小児における重症"肺動脈性"肺高血圧症の病態を再考する
    永井 礼子; 辻岡 孝郎; 藤本 隆憲; 谷口 宏太; 佐々木 理; 泉 岳; 山澤 弘州; 武田 充人, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 381, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 小児心筋疾患原因診断プロセスにおける課題 小児心筋症の原因診断における心筋生検の適応と役割
    武田 充人; 山澤 弘州; 泉 岳; 佐々木 理; 谷口 宏太; 辻岡 孝郎; 藤本 隆憲; 永井 礼子, 日本小児循環器学会雑誌, 35, Suppl.1, s1, 437, 2019年06月
    (NPO)日本小児循環器学会, 日本語
  • 小児期発症肺動脈性肺高血圧症におけるX遺伝子変異の役割
    永井 礼子[千田]; 新谷 正樹; 古谷 喜幸; 中山 智孝; 新居 正基; 稲井 慶; 中西 敏雄, 日本小児循環器学会雑誌, 34, Suppl.1, s1, 208, 2018年07月
    (NPO)日本小児循環器学会, 日本語
  • 遺伝性出血性末梢血管拡張症における遺伝子変異と臨床像
    千田 礼子; 新谷 正樹; 島田 光世; 古谷 喜幸; 稲井 慶; 松岡 留美子; 朴 仁三; 中西 敏雄, 日本小児循環器学会雑誌, 33, Suppl.1, s1, 101, 2017年07月
    (NPO)日本小児循環器学会, 日本語
  • 小児の肺動脈性肺高血圧へのアプローチ:最近のエビデンス 小児期発症肺動脈性肺高血圧症における遺伝子異常
    千田 礼子, 日本小児循環器学会雑誌, 32, Suppl.1, s1, 119, 2016年07月
    (NPO)日本小児循環器学会, 英語
  • 小児の肺動脈性肺高血圧へのアプローチ:最近のエビデンス 小児期発症肺動脈性肺高血圧症における遺伝子異常
    千田 礼子, 日本小児循環器学会雑誌, 32, Suppl.1, s1, 119, 2016年07月
    (NPO)日本小児循環器学会, 英語
  • 小児期発症肺動脈性肺高血圧症における遺伝子異常
    千田 礼子; 新谷 正樹; 野々山 恵章; 中西 敏雄, 呼吸と循環, 64, 5, S8, S8, 2016年05月
    (株)医学書院, 日本語
  • Genetics of Pulmonary Arterial Hypertension 小児期発症肺動脈性肺高血圧症における遺伝子異常
    千田 礼子; 新谷 正樹; 野々山 恵章; 中西 敏雄, 日本小児肺循環研究会プログラム・抄録集, 22回, 18, 18, 2016年02月
    日本小児肺循環研究会, 日本語
  • 小児期発症肺高血圧症の予後とその規定因子
    稲井 慶; 宮本 健志; 前田 潤; 千田 礼子; 高月 晋一; 中山 智孝; 古谷 喜幸; 山岸 敬幸; 佐地 勉; 中西 敏雄, 日本小児循環器学会雑誌, 31, Suppl.1, s1, 160, 2015年07月
    (NPO)日本小児循環器学会, 日本語
  • 肥大型心筋症患者の予後は予測できるのか?
    千田 礼子; 稲井 慶; 佐藤 弘樹; 島田 衣里子; 島田 光世; 古谷 道子; 古谷 喜幸; 川村 陽一; 松岡 瑠美子; 野々山 恵章; 中西 敏雄, 日本小児循環器学会雑誌, 31, Suppl.1, s1, 200, 2015年07月
    (NPO)日本小児循環器学会, 日本語
  • 頸部リンパ節腫脹が先行し、造影CTで評価を行った年長児川崎病の3例
    川村 陽一; 金井 貴志; 千田 礼子; 辻田 由喜; 竹下 誠一郎; 野々山 恵章, 日本小児科学会雑誌, 119, 2, 380, 380, 2015年02月
    (公社)日本小児科学会, 日本語
  • 小児期肺高血圧克服への新たなアプローチ 小児期発症肺動脈性肺高血圧症における予後規定因子
    千田 礼子; 佐藤 弘樹; 新谷 正樹; 中山 智孝; 川村 陽一; 古谷 喜幸; 稲井 慶; 佐地 勉; 松岡 瑠美子; 野々山 恵章; 中西 敏雄, 日本小児循環器学会雑誌, 30, Suppl., s149, s149, 2014年06月
    (NPO)日本小児循環器学会, 日本語
  • 川崎病におけるウリナスタチン・10%濃度免疫グロブリン製剤併用療法の治療成績
    川村 陽一; 金井 貴志; 千田 礼子; 辻田 由貴; 佐藤 一寿; 野々山 恵章, 日本小児循環器学会雑誌, 30, Suppl., s305, s305, 2014年06月
    (NPO)日本小児循環器学会, 日本語
  • 川崎病マウスモデルにおけるウリナスタチン投与の検討
    辻田 由喜; 川村 陽一; 金井 貴志; 千田 礼子; 野々山 恵章, 日本小児循環器学会雑誌, 30, Suppl., s306, s306, 2014年06月
    (NPO)日本小児循環器学会, 日本語
  • 川崎病急性期治療における10%濃度免疫グロブリン製剤の使用経験
    川村 陽一; 金井 貴志; 佐藤 弘樹; 千田 礼子; 辻田 由喜; 佐藤 一寿; 大澤 麻登里; 草野 智佳子; 野々山 恵章, 日本小児科学会雑誌, 118, 2, 338, 338, 2014年02月
    (公社)日本小児科学会, 日本語
  • 川崎病におけるウリナスタチン併用初期治療法の安全性に関する検討
    金井 貴志; 川村 陽一; 辻田 由喜; 佐藤 弘樹; 草野 智佳子; 中田 麻登里; 佐藤 一寿; 千田 礼子; 浅野 優; 野々山 恵章, 日本小児循環器学会雑誌, 29, Suppl., s274, s274, 2013年06月
    (NPO)日本小児循環器学会, 日本語
  • TCPC術後に肝硬変、肝細胞癌を発症し治療困難であった1例
    佐藤 一寿; 川村 陽一; 草野 智佳子; 千田 礼子; 釜江 智佳子; 金井 貴志; 松本 浩; 若松 太; 西山 光則; 野々山 恵章, 日本小児循環器学会雑誌, 29, Suppl., s278, s278, 2013年06月
    (NPO)日本小児循環器学会, 日本語
  • 川崎病のリスクスコア低値にもかかわらず追加治療を要した症例に関する検討
    川村 陽一; 金井 貴志; 佐藤 弘樹; 千田 礼子; 辻田 由喜; 佐藤 一寿; 大澤 麻登里; 草野 智佳子; 川口 裕之; 野々山 恵章, 日本小児科学会雑誌, 117, 2, 334, 334, 2013年02月
    (公社)日本小児科学会, 日本語
  • Clinical Outcomes of Mutation Carriers in Pulmonary Arterial Hypertension in Children
    Ayako Chida; Masaki Shintani; Hisato Yagi; Maya Fujiwara; Yasuko Kojima; Hiroki Sato; Shinichiro Imamura; Tomotaka Nakayama; Takahiro Ishiwata; Yoshiyuki Furutani; Kei Inai; Tsutomu Saji; Rumiko Matsuoka; Shigeaki Nonoyama; Toshio Nakanishi, CIRCULATION, 126, 21, 2012年11月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 特発性肺動脈性肺高血圧症におけるBMPR1B(ALK6)遺伝子変異
    千田 礼子; 新谷 正樹; 中山 智孝; 古谷 喜幸; 羽山 恵美子; 石渡 隆寛; 稲井 慶; 佐地 勉; 野々山 恵章; 中西 敏雄, 日本小児循環器学会雑誌, 28, Suppl., s197, s197, 2012年06月
    (NPO)日本小児循環器学会, 日本語
  • EBウイルス感染症に肺炎を合併した2例
    田村 義輝; 川村 陽一; 橋爪 浩臣; 森西 洋一; 滝沢 真理; 千田 礼子; 平山 健一, 小児科臨床, 65, 5, 1015, 1018, 2012年05月
    (株)日本小児医事出版社, 日本語
  • ANKH遺伝子変異を認めた頭蓋骨骨幹端異形成症の1例
    加藤 環; 松本 浩; 千田 礼子; 中村 康子; 梶原 伸介; 佐藤 正規; 若松 太; 野々山 恵章, 日本小児科学会雑誌, 116, 2, 400, 400, 2012年02月
    (公社)日本小児科学会, 日本語
  • ジアゾキサイドによる治療を要した新生児一過性高インスリン血性低血糖症4例について
    辻田 由喜; 山本 かずな; 藤田 基資; 三井 佳奈子; 加藤 環; 千田 礼子; 浅野 貴子; 松本 浩; 若松 太; 野々山 恵章, 日本小児科学会雑誌, 115, 11, 1807, 1807, 2011年11月
    (公社)日本小児科学会, 日本語
  • 特発性心筋症における遺伝子変異と臨床像
    千田 礼子; 稲井 慶; 島田 衣里子; 島田 光世; 古谷 喜幸; 畠井 芳穂; 松岡 瑠美子; 中西 敏雄, 日本小児循環器学会雑誌, 27, Suppl., s208, s208, 2011年06月
    (NPO)日本小児循環器学会, 日本語
  • 貧血、成長障害を契機に診断された若年性ネフロン癆の1例
    橋本 淳也; 浅野 貴子; 千田 礼子; 松本 浩; 子川 和宏; 野々山 恵章; 濱崎 祐子; 幡谷 浩史, 日本小児科学会雑誌, 115, 4, 840, 841, 2011年04月
    (公社)日本小児科学会, 日本語
  • 高インスリン性低血糖症の1新生児例
    千田 礼子; 本田 涼; 座波 清誉; 橋本 淳也; 西山 光則; 若松 太; 野々山 恵章, 日本小児科学会雑誌, 115, 3, 659, 659, 2011年03月
    (公社)日本小児科学会, 日本語
  • 肺動脈性肺高血圧症における遺伝子変異
    稲井 慶; 新谷 正樹; 千田 礼子; 島田 衣里子; 古谷 善幸; 松岡 瑠美子; 中西 敏雄; 中山 智孝; 佐地 勉, 日本小児科学会雑誌, 115, 2, 460, 460, 2011年02月
    (公社)日本小児科学会, 日本語
  • EBV感染症に肺炎を合併した2例
    田村 義輝; 川村 陽一; 橋爪 浩臣; 森西 洋一; 千田 礼子; 平山 健一, 防衛衛生, 58, 別冊, 76, 76, 2011年01月
    (一社)日本防衛衛生学会, 日本語
  • 突然の心肺機能停止により発見されたCraniometaphyseal dysplasiaの1乳児例
    千田 礼子; 柳川 洋一; 松本 浩; 野々山 恵章, 日本救急医学会関東地方会雑誌, 31, 84, 85, 2010年12月
    日本救急医学会-関東地方会, 日本語
  • NAPlr陽性で著明な管内増殖を呈したびまん性増殖性ループス腎炎の1例
    浅野 貴子; 橋本 淳也; 小倉 友美; 梶原 伸介; 千田 礼子; 釜江 智佳子; 松本 浩; 野々山 恵章; 尾田 高志; 長田 道夫, 日本小児腎臓病学会雑誌, 23, 1Suppl., 185, 185, 2010年06月
    (一社)日本小児腎臓病学会, 日本語
  • 急激な経過を辿ったHHV-7脳症の1例
    千田 礼子; 松本 浩; 浅野 貴子; 野々山 恵章, 日本小児科学会雑誌, 114, 2, 284, 284, 2010年02月
    (公社)日本小児科学会, 日本語
  • 新型インフルエンザで入院管理を行った2例
    内田 菜々; 川村 陽一; 橋爪 浩臣; 千田 礼子; 轟 伊佐雄, 防衛衛生, 57, 別冊, 89, 89, 2010年01月
    (一社)日本防衛衛生学会, 日本語
  • 感覚障害および失調を主症状とした小児Guillain-Barre症候群の1例
    千田 礼子; 座波 清誉; 磯部 清孝; 畠中 大輔; 辻田 由喜; 浅野 貴子; 松本 浩; 野々山 恵章; 筧 紘子; 山岡 明子, 脳と発達, 41, 6, 475, 475, 2009年11月
    (一社)日本小児神経学会, 日本語
  • 胎生期においてもRyRが機能しSRからのCa2+放出がCICRにおいて重要な役割を果たしている
    滝沢 真理; 石渡 隆寛; 金井 貴志; 黒川 貴幸; 千田 礼子; 川村 陽一; 西山 光則; 浅野 優; 野々山 恵章; 石田 英之, 日本小児循環器学会雑誌, 25, 3, 452, 452, 2009年05月
    (NPO)日本小児循環器学会, 日本語
  • ウリナスタチン先行療法は川崎病γグロブリン不応例の冠動脈合併症を著しく低下させる
    金井 貴志; 滝沢 真理; 川村 陽一; 佐藤 正規; 千田 礼子; 黒川 貴幸; 石渡 隆寛; 西山 光則; 竹下 誠一郎; 浅野 優; 野々山 恵章, 日本小児循環器学会雑誌, 25, 3, 555, 555, 2009年05月
    (NPO)日本小児循環器学会, 日本語
  • 小児期発症のChurg-Strauss症候群の1例
    佐藤 正規; 子川 和宏; 三井 佳奈子; 加藤 環; 千田 礼子; 今井 耕輔; 野々山 恵章, アレルギー, 58, 3-4, 411, 411, 2009年04月
    (一社)日本アレルギー学会, 日本語
  • 自衛隊福岡病院保険医療機関化後の小児科診療と今後の展望
    大川 貴司; 畠中 大輔; 千田 礼子; 本間 健一, 自衛隊福岡病院研究年報, 平成20年度, 1, 5, 2009年04月
    自衛隊福岡病院, 日本語
  • 当院で経験した骨髄炎が疑われた3例
    本田 涼; 橋本 淳也; 千田 礼子; 西山 光則; 若松 太; 野々山 惠章, 防衛衛生, 56, 別冊, 103, 103, 2009年01月
    (一社)日本防衛衛生学会, 日本語
  • 自衛隊福岡病院保険医療機関化後の小児科診療と今後の展望
    大川 貴司; 畠中 大輔; 千田 礼子; 本間 健一, 防衛衛生, 56, 別冊, 103, 103, 2009年01月
    (一社)日本防衛衛生学会, 日本語
  • 心外型総肺静脈還流異常合併の有無による無脾症候群の予後
    中村 真; 石川 司朗; 千田 礼子; 中右 弘一; 安田 和志; 石川 友一; 牛ノ濱 大也; 佐川 浩一; 総崎 直樹; 角 秀秋, 日本小児循環器学会雑誌, 24, 6, 742, 743, 2008年11月
    (NPO)日本小児循環器学会, 日本語
  • 無脾症候群の単心室におけるフォンタン手術に到達できない原因
    中村 真; 石川 司朗; 千田 礼子; 中右 弘一; 安田 和志; 石川 友一; 牛ノ濱 大也; 佐川 浩一; 総崎 直樹; 角 秀秋, 日本小児循環器学会雑誌, 24, 3, 290, 290, 2008年05月
    (NPO)日本小児循環器学会, 日本語
  • 小児期の心臓拡張障害
    千田 礼子; 石川 友一; 石川 司朗; 大川 貴司; 中右 弘一; 安田 和志; 中村 真; 牛ノ濱 大也; 佐川 浩一, 日本小児循環器学会雑誌, 24, 3, 362, 362, 2008年05月
    (NPO)日本小児循環器学会, 日本語
  • 心不全の指標となる血漿BNP値とNT-proBNP値はどのように異なるのか?
    中右 弘一; 石川 友一; 石川 司朗; 千田 礼子; 安田 和志; 中村 真; 牛ノ濱 大也; 佐川 浩一; 総崎 直樹, 日本小児循環器学会雑誌, 24, 3, 390, 390, 2008年05月
    (NPO)日本小児循環器学会, 日本語
  • 乳児期に急性うっ血性心不全を呈する僧帽弁腱索断裂
    千田 礼子; 成田 純任; 石川 司朗; 石川 友一; 中村 真; 牛ノ濱 大也; 佐川 浩一; 角 秀秋, 日本小児循環器学会雑誌, 23, 3, 279, 279, 2007年05月
    (NPO)日本小児循環器学会, 日本語
  • 5歳時に意識障害,嘔吐にて発症した古典型シトルリン血症の1例
    岩崎 環; 千田 礼子; 鈴木 繁; 辻 陽一郎; 子川 和宏; 高柳 正樹; 野々山 恵章, 日本小児科学会雑誌, 110, 2, 229, 229, 2006年02月
    (公社)日本小児科学会, 日本語
  • 乳児期早期にNIPPV導入に成功した先天性中枢性肺胞低換気症候群(CCHS)の一症例
    千田 礼子; 石渡 隆寛; 徳富 智明; 畠中 大輔; 三井 佳奈子; 若松 太; 浅野 優; 野々山 恵章, 日本小児科学会雑誌, 110, 2, 344, 344, 2006年02月
    (公社)日本小児科学会, 日本語
  • 先天性中枢性低換気症候群の一例
    畠中 大輔; 徳富 智明; 三井 佳奈子; 千田 礼子; 石渡 隆寛; 若松 太; 浅野 優; 野々山 恵章, 防衛衛生, 53, 別冊, 109, 109, 2006年01月
    (一社)日本防衛衛生学会, 日本語
  • 高度側彎,肺高血圧症,右心不全により急性呼吸不全をきたした,肥満を伴わないPrader-Willi症候群(PWS)の1症例
    千田 礼子; 徳富 智明; 堀内 勝行; 石渡 隆寛; 茂木 陽; 若松 太; 浅野 優; 関根 勇夫; 野々山 恵章; 渡邉 泰伸; 朝妻 孝仁, 日本小児科学会雑誌, 109, 10, 1284, 1285, 2005年10月
    (公社)日本小児科学会, 日本語
  • 5歳時に意識障害,嘔吐で発症した古典型シトルリン血症の1例
    岩崎 環; 千田 礼子; 鈴木 繁; 徳富 智明; 今井 耕輔; 辻 陽一郎; 子川 和宏; 関根 勇夫; 野々山 恵章; 高柳 正樹, 日本小児科学会雑誌, 109, 10, 1285, 1285, 2005年10月
    (公社)日本小児科学会, 日本語
  • 夏期におけるRSV感染症の2例
    千田 礼子; 石井 茂樹; 磯崎 淳; 古池 雄治; 黒木 康富; 若松 太; 藤塚 聡, 防衛衛生, 52, 別冊, 68, 68, 2004年12月
    (一社)日本防衛衛生学会, 日本語
■ 主な担当授業
  • 応用社会行動科学, 2024年, 修士課程, 医学院
  • 応用社会行動科学, 2024年, 修士課程, 医学院
  • 応用社会行動科学, 2024年, 修士課程, 医学院
■ 共同研究・競争的資金等の研究課題
  • PTGIS遺伝子異常がもたらす、中小動脈疾患の病態解明
    科学研究費助成事業
    2025年04月 - 2028年03月
    永井 礼子; 赤川 浩之; 岡本 孝之; 小西 崇夫; 佐藤 弘樹
    日本学術振興会, 基盤研究(C), 北海道大学, 25K11291
  • 遺伝学的背景に基づいた、東アジアにおける小児期肺動脈性肺高血圧症の臨床像の解明
    2023年 - 2026年
    永井 礼子
    日本小児循環器学会 研究課題A
  • 令和6年度 小児医学研究振興財団研究助成金(小児医学領域全般)
    2025年03月
    永井 礼子
  • 深層学習を活用した多面的病理学的検討による、小児期発症肺高血圧症の病態解明
    2022年 - 2025年
    永井 礼子
    日本学術振興会 科学研究費助成事業 基盤研究(C)
  • 川野小児医学奨学財団研究助成(一般枠)
    2023年06月
    永井 礼子
  • 2019年度 GSKジャパン研究助成
    2019年11月 - 2021年03月
    永井 礼子
    研究代表者, 競争的資金
  • ミトコンドリア心筋症の新規診断法の確立
    科学研究費助成事業 基盤研究(C)
    2019年 - 2021年
    武田 充人
    日本学術振興会, 競争的資金
  • 肺動脈性肺高血圧症の新規治療法の開発
    科学研究費助成事業 若手研究
    2019年 - 2021年
    永井 礼子
    日本学術振興会, 研究代表者, 競争的資金
  • 先天性心疾患を伴う肺高血圧症例の多施設症例登録研究
    日本医療研究開発機構(AMED)
    2021年
    土井 庄三郎
    研究分担者
  • 2019年度 アクテリオン契約研究助成
    2019年
    永井 礼子
  • 肺動脈性肺高血圧症の新規原因遺伝子の同定と機能解析
    科学研究費助成事業 若手研究(B)
    2015年 - 2017年
    永井 礼子
    日本学術振興会, 研究代表者, 競争的資金
  • 小児期肺動脈性肺高血圧症の発症に関わる新しい伝達経路の解明
    科学研究費助成事業 基盤研究(C)
    2012年 - 2014年
    杉山 央
    日本学術振興会, 競争的資金
  • 令和2年度 寿原記念財団 研究助成
    永井 礼子
  • 2020年度 武田科学振興財団 医学系研究助成
    永井 礼子
  • 2020年度 秋山記念生命科学振興財団 研究助成
    永井 礼子